Rhumbline Advisers Regenxbio Inc. Transaction History

Rhumbline Advisers

  • $104 Billion
  • Q1 2025

A detailed history of Rhumbline Advisers transactions in Regenxbio Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 71,155 shares of RGNX stock, worth $690,915. This represents 0.0% of its overall portfolio holdings.

Number of Shares
71,155
Previous 74,269 4.19%
Holding current value
$690,915
Previous $574,000 2.96%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Apr 08, 2025
SELL
$5.92 - $8.7 $18,434 - $27,091
-3,114 Reduced 4.19%
71,155 $557,000
Q4 2024

Jan 30, 2025
SELL
$7.23 - $11.56 $294,665 - $471,139
-40,756 Reduced 35.43%
74,269 $574,000
Q3 2024

Nov 12, 2024
SELL
$10.49 - $14.39 $36,725 - $50,379
-3,501 Reduced 2.95%
115,025 $1.21 Million
Q2 2024

Aug 01, 2024
BUY
$11.51 - $21.53 $103,440 - $193,490
8,987 Added 8.2%
118,526 $1.39 Million
Q1 2024

May 09, 2024
SELL
$12.17 - $24.61 $21,808 - $44,101
-1,792 Reduced 1.61%
109,539 $2.31 Million
Q4 2023

Feb 08, 2024
BUY
$12.89 - $20.82 $60,544 - $97,791
4,697 Added 4.4%
111,331 $2 Million
Q3 2023

Nov 09, 2023
BUY
$16.46 - $19.99 $24,887 - $30,224
1,512 Added 1.44%
106,634 $1.76 Million
Q2 2023

Aug 08, 2023
BUY
$17.23 - $21.71 $34,046 - $42,898
1,976 Added 1.92%
105,122 $2.1 Million
Q1 2023

May 11, 2023
BUY
$18.08 - $24.55 $60,821 - $82,586
3,364 Added 3.37%
103,146 $1.95 Million
Q4 2022

Feb 14, 2023
SELL
$20.4 - $24.73 $79,519 - $96,397
-3,898 Reduced 3.76%
99,782 $2.26 Million
Q3 2022

Nov 10, 2022
BUY
$22.29 - $35.04 $140,984 - $221,628
6,325 Added 6.5%
103,680 $2.74 Million
Q2 2022

Aug 11, 2022
BUY
$19.35 - $35.04 $192,106 - $347,877
9,928 Added 11.36%
97,355 $2.41 Million
Q1 2022

May 12, 2022
BUY
$24.62 - $34.31 $134,006 - $186,749
5,443 Added 6.64%
87,427 $2.9 Million
Q4 2021

Feb 10, 2022
SELL
$30.19 - $40.28 $65,300 - $87,125
-2,163 Reduced 2.57%
81,984 $2.68 Million
Q3 2021

Nov 12, 2021
SELL
$29.09 - $45.68 $251,163 - $394,401
-8,634 Reduced 9.31%
84,147 $3.53 Million
Q2 2021

Aug 05, 2021
BUY
$32.46 - $40.48 $382,021 - $476,409
11,769 Added 14.53%
92,781 $3.61 Million
Q1 2021

May 06, 2021
BUY
$33.61 - $49.95 $317,043 - $471,178
9,433 Added 13.18%
81,012 $2.76 Million
Q4 2020

Feb 10, 2021
SELL
$26.52 - $49.35 $116,131 - $216,103
-4,379 Reduced 5.77%
71,579 $3.25 Million
Q3 2020

Nov 12, 2020
SELL
$27.01 - $40.26 $287,602 - $428,688
-10,648 Reduced 12.29%
75,958 $2.09 Million
Q2 2020

Aug 13, 2020
SELL
$27.75 - $43.44 $142,191 - $222,586
-5,124 Reduced 5.59%
86,606 $3.19 Million
Q1 2020

May 06, 2020
BUY
$21.5 - $54.2 $60,114 - $151,543
2,796 Added 3.14%
91,730 $2.97 Million
Q4 2019

Feb 05, 2020
BUY
$34.54 - $44.87 $326,472 - $424,111
9,452 Added 11.89%
88,934 $3.64 Million
Q3 2019

Oct 23, 2019
SELL
$31.84 - $50.88 $15,283 - $24,422
-480 Reduced 0.6%
79,482 $2.83 Million
Q2 2019

Aug 14, 2019
BUY
$42.0 - $59.29 $292,026 - $412,243
6,953 Added 9.52%
79,962 $4.11 Million
Q1 2019

May 01, 2019
SELL
$40.82 - $62.45 $32,656 - $49,960
-800 Reduced 1.08%
73,009 $4.18 Million
Q4 2018

Jan 31, 2019
BUY
$39.11 - $75.15 $686,654 - $1.32 Million
17,557 Added 31.21%
73,809 $3.1 Million
Q3 2018

Nov 07, 2018
SELL
$65.0 - $82.15 $5,590 - $7,064
-86 Reduced 0.15%
56,252 $4.25 Million
Q2 2018

Aug 06, 2018
BUY
$27.2 - $74.35 $788,854 - $2.16 Million
29,002 Added 106.09%
56,338 $4.04 Million
Q1 2018

May 02, 2018
SELL
$24.05 - $37.5 $7,575 - $11,812
-315 Reduced 1.14%
27,336 $816,000
Q3 2017

Nov 06, 2017
BUY
$18.0 - $32.95 $497,718 - $911,100
27,651
27,651 $911,000

Others Institutions Holding RGNX

# of Institutions
182
Shares Held
45.4M
Call Options Held
64.9K
Put Options Held
103K
View Full List

About REGENXBIO Inc.

RGNX Quotes by TradingView
  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $420M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email